Literature DB >> 20028212

p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.

Larisa V Debelenko1, Antonio R Perez-Atayde, Steven G Dubois, Holcombe E Grier, Sung-Yun Pai, Robert C Shamberger, Harry P W Kozakewich.   

Abstract

The spectrum of lipomatous tumors differs in the adult and pediatric populations, with liposarcoma being rare in children. Nearly 10% of individuals with Li-Fraumeni syndrome develop sarcomas in the first 2 decades of life; however, the frequency of sarcoma types and subtypes in this syndrome is unknown. Two atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDLS) were identified in the pathology files of our institution in young children from "classical" Li-Fraumeni and Li-Fraumeni variant kindreds with a known germline TP53 mutation (Y220C) in one of the families. The patients were 5 and 6 years of age and the ALT/WDLSs were the first expression of the syndrome. The tumors had a high degree of cellular atypia and differed from sporadic ALT/WDLS by strong nuclear immunoreactivity for p53 and absent mdm2 expression. This is the first report of 2 ALT/WDLSs presenting in children before 10 years of age, both in association with Li-Fraumeni syndrome/variant. ALT/WDLS in a young child should raise the possibility of a cancer predisposition syndrome and, in this setting, the p53(+)/mdm2(-) immunophenotype might be characteristic. Recognition of this lesion and its association is important for early diagnosis and subsequent tumor surveillance in the proband and affected family members.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20028212     DOI: 10.2350/09-08-0694-OA.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  7 in total

1.  Aberrant AKT activation drives well-differentiated liposarcoma.

Authors:  Alejandro Gutierrez; Eric L Snyder; Adrian Marino-Enriquez; Yi-Xiang Zhang; Stefano Sioletic; Elena Kozakewich; Ruta Grebliunaite; Wen-Bin Ou; Ewa Sicinska; Chandrajit P Raut; George D Demetri; Antonio R Perez-Atayde; Andrew J Wagner; Jonathan A Fletcher; Christopher D M Fletcher; A Thomas Look
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Liposarcoma in children and young adults: a clinicopathologic and molecular study of 23 cases in one of the largest institutions of China.

Authors:  Ran Peng; Nan Li; Ting Lan; Huijiao Chen; Tianhai Du; Xin He; Min Chen; You Xie; Zhang Zhang; Wei Zhao; Hongying Zhang
Journal:  Virchows Arch       Date:  2021-03-18       Impact factor: 4.064

3.  Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation.

Authors:  Navid Sadri; Lea F Surrey; Douglas L Fraker; Paul J Zhang
Journal:  Virchows Arch       Date:  2014-03-05       Impact factor: 4.064

4.  Well-differentiated lipomatous neoplasms with p53 alterations: a clinicopathological and molecular study of eight cases with features of atypical pleomorphic lipomatous tumour.

Authors:  Phoebe M Hammer; Christian A Kunder; Brooke E Howitt; Gregory W Charville
Journal:  Histopathology       Date:  2022-01-05       Impact factor: 5.087

5.  HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.

Authors:  Wen-Bin Ou; Jiaqing Zhu; Grant Eilers; Xuhui Li; Ye Kuang; Li Liu; Adrián Mariño-Enríquez; Ziqin Yan; Hailong Li; Fanguo Meng; Haimeng Zhou; Qing Sheng; Jonathan A Fletcher
Journal:  Oncotarget       Date:  2015-04-30

Review 6.  MDM2 Amplified Sarcomas: A Literature Review.

Authors:  Raf Sciot
Journal:  Diagnostics (Basel)       Date:  2021-03-11

Review 7.  Update of Pediatric Lipomatous Lesions: A Clinicopathological, Immunohistochemical and Molecular Overview.

Authors:  Eline Ameloot; Fleur Cordier; Jo Van Dorpe; David Creytens
Journal:  J Clin Med       Date:  2022-03-31       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.